Ottawa, ON – Researchers funded by the Canadian Institutes of Health Research (CIHR) and the Canadian Diabetes Association (CDA) say they have identified an unsuspected role of a protein named SHP-1 that could constitute a new therapeutic path against Type 2 diabetes.
Under the direction of professor Andr Marette (Laval University), Nicole Beauchemin (McGill University), Martin Oliver (McGill University Health Centre) and Katherine Siminovitch (University of Toronto) were part of a Canadian and American team which published an article in the May issue of Nature Medicine that explains the role of SHP-1 in the control of blood glucose.
The researchers already knew that SHP-1 played a role in regulating the immune system. However, no one had previously taken the time to verify if this protein was involved in the regulation of metabolism. This is precisely what this team of Canadian and American researchers did, thanks to a series of mutant or genetically modified mice producing little or no SHP-1.
“Our results indicate that these mice are extremely sensitive to insulin and, consequently, they are very effective in metabolising glucose at the level of the liver and the muscles,” notes Andr Marette. In addition, the researchers highlighted that SHP-1 inhibits the decomposition of insulin by the liver. “This could explain the increase in the insulin concentrations of certain metabolic disorders associated with obesity,” he says.
“By inhibiting the activity of SHP-1, it would perhaps be possible to restore better control of blood glucose,” he adds. “The difficulty, however, is to reach that point without blocking the essential part played by this protein in the immune system. The SHP-1 protein is present in humans, but its role in the regulation of the metabolism of glucose and in the development of Type 2 diabetes remains to be shown.